Our Partners
Built for every stakeholder in the cell therapy ecosystem
Nalmera works with the full range of organizations required to bring advanced cell therapies to patients — from health systems and governments to investors, biotech partners, and academic centers.
Hospitals & Health Systems
Establish a world-class cell therapy program within your institution.
For hospitals and health systems ready to offer CAR-T and advanced cell therapies, Nalmera provides the complete implementation infrastructure — from GMP manufacturing setup and clinical pathway design to regulatory approval and workforce training.
Common challenges
- No existing cell therapy manufacturing capability
- Regulatory approval pathways are complex and unfamiliar
- Clinical teams need structured training and protocols
- Financial sustainability of the program is uncertain
What Nalmera delivers
- GMP facility design and commissioning
- Clinical protocol development and safety frameworks
- Regulatory strategy and dossier preparation
- Staff training across clinical and manufacturing roles
- Reimbursement strategy and financial modeling
Governments & Health Ministries
Build national cell therapy capability — and the access that comes with it.
Governments and health ministries seeking to establish sovereign cell therapy capability can partner with Nalmera to design, fund, and implement national programs that serve their populations and reduce dependence on expensive imported therapies.
Common challenges
- No domestic manufacturing or clinical infrastructure
- High cost of importing therapies from foreign markets
- Regulatory frameworks not yet adapted for advanced therapies
- Need for a sustainable, locally-owned program model
What Nalmera delivers
- National program feasibility and design
- Public-private partnership structuring
- Regulatory framework development and HTA support
- Domestic manufacturing capability establishment
- Long-term sustainability and governance planning
Investors & Funders
Deploy capital into cell therapy programs built to succeed.
For investors and philanthropic funders, Nalmera provides the operational expertise and implementation infrastructure that transforms capital into functioning programs — with the governance, quality systems, and financial models required for long-term viability.
Common challenges
- Lack of operational expertise to execute alongside capital
- High implementation risk in complex regulatory environments
- Uncertainty about program sustainability post-investment
- Need for measurable milestones and outcome tracking
What Nalmera delivers
- Program feasibility and investment case development
- Implementation risk assessment and mitigation
- Milestone-based program management
- Financial sustainability modeling
- Outcome tracking and reporting frameworks
Biotech & Pharma Partners
Expand your therapy's reach into new markets — without building the infrastructure yourself.
For biotech and pharmaceutical companies with approved or pipeline cell therapies, Nalmera provides the market-entry infrastructure to establish manufacturing, clinical, and commercial operations in new geographies.
Common challenges
- Complex local regulatory requirements for market entry
- No existing manufacturing or distribution infrastructure
- Clinical and commercial teams not yet established
- Technology transfer to local partners is high-risk
What Nalmera delivers
- Market entry strategy and regulatory pathway
- Technology transfer and local manufacturing setup
- Commercial model and reimbursement strategy
- Clinical operations and medical affairs support
- Partner identification and relationship management
Academic Medical Centers
Translate your research into a clinical program that treats patients.
Academic medical centers with cell therapy research programs can partner with Nalmera to bridge the gap between laboratory discovery and clinical delivery — building the manufacturing, regulatory, and operational infrastructure to treat patients.
Common challenges
- Research expertise does not translate directly to clinical operations
- GMP manufacturing requirements are distinct from research-grade production
- Regulatory approval for investigational and commercial therapies is complex
- Funding and financial sustainability for clinical programs
What Nalmera delivers
- Research-to-clinic translation strategy
- GMP manufacturing setup alongside research facilities
- IND/CTA and commercial regulatory support
- Clinical trial operations and patient pathway design
- Commercialization and sustainability planning
Philanthropic Organizations
Fund programs designed to maximize patient access and impact.
Philanthropic organizations committed to expanding access to life-saving therapies can partner with Nalmera to ensure their funding is deployed into programs with the operational rigor, clinical quality, and sustainability required to achieve lasting impact.
Common challenges
- Ensuring funded programs are operationally viable
- Measuring and demonstrating patient impact
- Avoiding dependency on perpetual external funding
- Navigating complex healthcare system environments
What Nalmera delivers
- Program design aligned with philanthropic objectives
- Operational and clinical quality assurance
- Patient access and equity frameworks
- Impact measurement and reporting
- Sustainability planning for post-grant independence
What unites our partners
One shared goal: patients treated
Whether you're a hospital building your first program, a government establishing national capability, or an investor deploying capital into a new market — the measure of success is the same.
Nalmera exists to make that outcome achievable — for every partner, in every context.
Ready to start a conversation?
Tell us about your program goals and we'll outline how Nalmera can help you achieve them.